{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:26Z","timestamp":1790470226121,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400145"],"award-info":[{"award-number":["81400145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81530046"],"award-info":[{"award-number":["81530046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81621001"],"award-info":[{"award-number":["81621001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Talents Fund","award":["2015000021223ZK39"],"award-info":[{"award-number":["2015000021223ZK39"]}]},{"name":"Science and Technology Project of Guangdong Province of China","award":["2016B030230003"],"award-info":[{"award-number":["2016B030230003"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bbmt.2017.04.023","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T01:04:02Z","timestamp":1493341442000},"page":"1303-1310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["IFN-\u03b1 Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiao-Dong","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8087","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.04.023_bib0010","first-page":"331","article-title":"Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON)","volume":"87","author":"Mu\u00f1oz","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0015","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0020","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000204473","article-title":"Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient","volume":"89","author":"McSweeney","year":"1993","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0030","doi-asserted-by":"crossref","first-page":"e23619","DOI":"10.4161\/onci.23619","article-title":"Interferon \u03b1 may be back on track to treat acute myeloid leukemia","volume":"2","author":"Smits","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-\u03b1 in acute myeloid leukemia: an old drug revisited","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0040","first-page":"31","article-title":"Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon","volume":"2","author":"Faber","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.bmt.1700793","article-title":"Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b","volume":"19","author":"Singhal","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.21346","article-title":"Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation","volume":"84","author":"Gesundheit","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0060","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1200\/JCO.2012.48.0442","article-title":"Successful treatment of relapsed acute myeloid leukemia without chemotherapy","volume":"34","author":"Tang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0065","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bbmt.2015.06.014","article-title":"Interferon-\u03b1: a potentially effective treatment for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Mo","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0070","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-09-0691","article-title":"Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies","volume":"15","author":"Xiao-Jun","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0075","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","article-title":"Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation","volume":"15","author":"Huang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0090","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00277-011-1285-1","article-title":"Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Zhao","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/bmt.2011.121","article-title":"Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT","volume":"47","author":"Zhao","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0100","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"Diagnosis and management of acute graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0115","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0120","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF01789019","article-title":"Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2","volume":"35","author":"Morecki","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11596-007-0509-z","article-title":"Antitumor effect of interferon-alpha on U937 human acute leukemia cells in vitro and its molecular mechanism","volume":"27","author":"Zhang","year":"2007","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0145","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/bjc.1984.125","article-title":"Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia","volume":"49","author":"Rohatiner","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2009.08029.x","article-title":"Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis","volume":"149","author":"Berneman","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0155","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00277-012-1560-9","article-title":"Pegylated interferon \u03b12a induces complete remission of acute myeloid leukemia in a post essential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation","volume":"92","author":"Dagorne","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0160","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.V78.12.3306.3306","article-title":"Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]","volume":"78","author":"Klingemann","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/bmt.2009.26","article-title":"Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect","volume":"44","author":"Huang","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12591","volume":"96","author":"Mo","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0175","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/leu.2010.133","article-title":"Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation","volume":"24","author":"Lankester","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0180","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/10428194.2016.1239264","article-title":"The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission","volume":"58","author":"Zhao","year":"2017","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1445-5994.2001.00013.x","article-title":"Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation","volume":"31","author":"Grigg","year":"2001","journal-title":"Intern Med J"},{"key":"10.1016\/j.bbmt.2017.04.023_bib0190","first-page":"2583","article-title":"Interferon \u03b1: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion","volume":"127","author":"Mo","year":"2014","journal-title":"Chin Med J"}],"updated-by":[{"DOI":"10.1016\/j.bbmt.2019.03.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000}}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T12:31:17Z","timestamp":1601987477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117304329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1083879117304329"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.023","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bbmt.2019.03.005","asserted-by":"object"}]},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b1 Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}